<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238991</url>
  </required_header>
  <id_info>
    <org_study_id>B2571001</org_study_id>
    <secondary_id>3134K1-2207</secondary_id>
    <nct_id>NCT01238991</nct_id>
  </id_info>
  <brief_title>Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
  <official_title>A Phase Iia, Multicenter, Treatment Assigned, Open-label, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this long term extension study is to assess safety, tolerability and
      immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD
      who were randomized in the preceding P2 double blind studies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (AEs) by Severity</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Number of mild, moderate, and severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormalities in Neurological Examination</measure>
    <time_frame>Baseline of the preceding studies through 24 months of this study</time_frame>
    <description>Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerve Function, Cranial Nerve II, Sensory Function, Motor Function, Coordination, Gait and Station, Reflexes and Deep Tendon Reflexes.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Anti-A-beta IgG (Immunoglobulin G) Titer at Specified Visits</measure>
    <time_frame>Baseline of preceding studies to month 24 of this study (Week 210)</time_frame>
    <description>Geometric mean of anti-a-beta IgG titer from baseline of the preceding studies through the end of this study</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-A-beta IgM (Immunoglobulin M) Titer at Specified Visits</measure>
    <time_frame>Baseline of preceding studies to month 24 of this study (Week 210)</time_frame>
    <description>Geotmetric mean of anti-a-beta IgM titer from baseline of the preceding studies through the end of this study</description>
  </other_outcome>
  <other_outcome>
    <measure>The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 26, 52, 78 and 104.</measure>
    <time_frame>Baseline up to 24 Months</time_frame>
    <description>The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11, with higher scores indicating a greater degree of impairment. The total score ranges from 0 (no impairment) to 70 (worst impairment).</description>
  </other_outcome>
  <other_outcome>
    <measure>The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 26, 52,78 and 104.</measure>
    <time_frame>Baseline up to 24 Months</time_frame>
    <description>The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 26, 52, 78 and 104.</measure>
    <time_frame>Baseline up to 24 Months</time_frame>
    <description>The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit - y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants' observed baseline scores in the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 12, 26, 36, 52, 66, 78, 91 and 104.</measure>
    <time_frame>Baseline up to 24 Months</time_frame>
    <description>The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points, and any score equal to or lower than 26 points indicates cognitive impairment.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>ACC-001 (3 micrograms) + QS-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active vaccine dose of 3 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACC-001 (10 micrograms) + QS-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active vaccine dose of 10 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACC-001 (30 micrograms) + QS-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active vaccine dose of 30 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACC-001</intervention_name>
    <description>IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18</description>
    <arm_group_label>ACC-001 (3 micrograms) + QS-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACC-001</intervention_name>
    <description>IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18</description>
    <arm_group_label>ACC-001 (10 micrograms) + QS-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACC-001</intervention_name>
    <description>IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18</description>
    <arm_group_label>ACC-001 (30 micrograms) + QS-21</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects randomized under previous 3134K1-2202-JA (NCT00752232) and 3134K1-2206-JA
             (NCT00959192) and met all inclusion criteria and non of the exclusion criteria.

          -  Screening brain MRI scan is consistent with the diagnosis of AD.

          -  MMSE score 10 and above.

        Exclusion Criteria:

          -  Significant neurological diseases other than AD.

          -  Brain MRI evidence of vasogenic edema during the preceding studies.

          -  Clinically significant illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>52 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meitetsu Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>451-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital</name>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Atsugi Hospital</name>
      <address>
        <city>Atsugi</city>
        <state>Kanagawa</state>
        <zip>243-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University East Hospital</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <zip>252-0380</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suwa Red Cross Hospital</name>
      <address>
        <city>Suwa</city>
        <state>Nagano</state>
        <zip>392-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo Tokyo Koto Geriatric Medical Center</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tokyo Jikei University School of Medicine</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Central Hospital of the Mutual Aid Association of Public School Teachers</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>158-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tazuke Kofukai Medical Research Institute Kitano Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2571001&amp;StudyName=Long%20Term%20Extension%20Study%20Evaluating%20Safety%2C%20Tolerability%20And%20Immunogenicity%20Of%20ACC-001%20In%20Japanese%20Subjects%20With%20Mild%20To%20Moderate%20Alzhe</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <results_first_submitted>December 12, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>QS 21</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study enrolled those who completed the preceding studies (NCT00752232 and NCT00959192), where active vaccine ACC-001 (3, 10 or 30 μg) + adjuvant QS-21 (50 μg), as well as ACC-001, QS-21 and phosphate buffered saline (PBS) alone, were administered at Day 1, month 3, 6, 9 and 12 and at Day 1, month 1, 3, 6 and 12, respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3 μg ACC-001+QS-21</title>
          <description>A group of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P2">
          <title>QS-21+(3 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P3">
          <title>10 μg ACC-001+QS-21</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P4">
          <title>10 μg ACC-001+ (10 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P5">
          <title>QS-21+(10 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P6">
          <title>PBS+(10 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P7">
          <title>30 μg ACC-001+QS-21</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P8">
          <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P9">
          <title>QS-21+(30 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="P10">
          <title>PBS+(30 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver's request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Admission to a nursing home</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3 μg ACC-001+QS-21</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B2">
          <title>QS-21+(3 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B3">
          <title>10 μg ACC-001+QS-21</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B4">
          <title>10 μg ACC-001+ (10 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B5">
          <title>QS-21+(10 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B6">
          <title>PBS+(10 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B7">
          <title>30 μg ACC-001+QS-21</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B8">
          <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B9">
          <title>QS-21+(30 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B10">
          <title>PBS+(30 μg ACC-001+QS-21)</title>
          <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="2"/>
            <count group_id="B11" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="9.8"/>
                    <measurement group_id="B2" value="73.3" spread="9.2"/>
                    <measurement group_id="B3" value="67.5" spread="9.8"/>
                    <measurement group_id="B4" value="69.5" spread="6.9"/>
                    <measurement group_id="B5" value="65.2" spread="6.7"/>
                    <measurement group_id="B6" value="70.5" spread="7.8"/>
                    <measurement group_id="B7" value="73.9" spread="5.4"/>
                    <measurement group_id="B8" value="71.2" spread="2"/>
                    <measurement group_id="B9" value="64" spread="7.1"/>
                    <measurement group_id="B10" value="68.5" spread="2.1"/>
                    <measurement group_id="B11" value="69.2" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Emergent Adverse Events (AEs) by Severity</title>
        <description>Number of mild, moderate, and severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>The population for safety analysis consisted of all enrolled participants who received at least one injection of study medication in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>3 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) or PBS in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>30 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>30 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) or PBS in the preceding studies and active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Adverse Events (AEs) by Severity</title>
          <description>Number of mild, moderate, and severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)</description>
          <population>The population for safety analysis consisted of all enrolled participants who received at least one injection of study medication in this study.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data</title>
        <description>Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>The population for safety analysis consisted of all enrolled participants who received at least one injection of study medication in this study. Since the study was early terminated and the data could not be obtained as planned, the MRI data were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>3 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) or PBS in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>30 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>30 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) or PBS in the preceding studies and active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data</title>
          <description>Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.</description>
          <population>The population for safety analysis consisted of all enrolled participants who received at least one injection of study medication in this study. Since the study was early terminated and the data could not be obtained as planned, the MRI data were not summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormalities in Neurological Examination</title>
        <description>Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerve Function, Cranial Nerve II, Sensory Function, Motor Function, Coordination, Gait and Station, Reflexes and Deep Tendon Reflexes.</description>
        <time_frame>Baseline of the preceding studies through 24 months of this study</time_frame>
        <population>The population for safety analysis consisted of all enrolled participants who received at least one injection of study medication in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>3 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) or PBS in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>30 μg ACC-001 Treat</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>30 μg Control</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) or PBS in the preceding studies and active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Neurological Examination</title>
          <description>Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerve Function, Cranial Nerve II, Sensory Function, Motor Function, Coordination, Gait and Station, Reflexes and Deep Tendon Reflexes.</description>
          <population>The population for safety analysis consisted of all enrolled participants who received at least one injection of study medication in this study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Speech</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cranial Nerve Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cranial Nerve II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coordination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gait and Station</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reflexes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Tendon Reflexes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Anti-A-beta IgG (Immunoglobulin G) Titer at Specified Visits</title>
        <description>Geometric mean of anti-a-beta IgG titer from baseline of the preceding studies through the end of this study</description>
        <time_frame>Baseline of preceding studies to month 24 of this study (Week 210)</time_frame>
        <population>The immunogenicity analysis population consisted of those in the safety analysis population who had baseline immunogenicity evaluation in the preceding study and at least one immunogenicity evaluation post injection.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>QS-21+(3 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg ACC-001+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>QS-21+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>PBS+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O7">
            <title>30 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O8">
            <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O9">
            <title>QS-21+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O10">
            <title>PBS+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21(50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-A-beta IgG (Immunoglobulin G) Titer at Specified Visits</title>
          <description>Geometric mean of anti-a-beta IgG titer from baseline of the preceding studies through the end of this study</description>
          <population>The immunogenicity analysis population consisted of those in the safety analysis population who had baseline immunogenicity evaluation in the preceding study and at least one immunogenicity evaluation post injection.</population>
          <units>Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-study (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O8" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" lower_limit="38.1" upper_limit="95.5"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="67.2" lower_limit="34.7" upper_limit="130.1"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O8" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=4, 2, 7, 0, 3, 0, 5, 0, 2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.5" lower_limit="18.2" upper_limit="1381.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="73.5" lower_limit="36.6" upper_limit="147.2"/>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="797.2" lower_limit="49.7" upper_limit="12776.7"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="1346.8" lower_limit="289.6" upper_limit="6264.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="924.1" lower_limit="142.2" upper_limit="6003.5"/>
                    <measurement group_id="O8" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=4, 2, 7, 0, 3, 0, 5, 0, 2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3202.0" lower_limit="168.8" upper_limit="60744.5"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="2950.3" lower_limit="837.0" upper_limit="10399.3"/>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="2543.1" lower_limit="969.3" upper_limit="6672.1"/>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494.2" lower_limit="49.1" upper_limit="4970.9"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="638.8" lower_limit="160.2" upper_limit="2547.6"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="386.9" lower_limit="87.7" upper_limit="1707.3"/>
                    <measurement group_id="O8" value="61.3" lower_limit="34.9" upper_limit="107.6"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6174.8" lower_limit="1628.1" upper_limit="23419.5"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="5696.9" lower_limit="2541.3" upper_limit="12771.2"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="5266.4" lower_limit="1852.1" upper_limit="14975.0"/>
                    <measurement group_id="O8" value="207.5" lower_limit="24.9" upper_limit="1726.5"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4239.5" lower_limit="895.3" upper_limit="20075.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="3471.2" lower_limit="1569.0" upper_limit="7680.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="5014.4" lower_limit="1788.3" upper_limit="14060.5"/>
                    <measurement group_id="O8" value="166.0" lower_limit="20.3" upper_limit="1355.0"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1292.4" lower_limit="263.8" upper_limit="6331.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="1122.5" lower_limit="502.5" upper_limit="2507.3"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="1765.8" lower_limit="638.5" upper_limit="4883.6"/>
                    <measurement group_id="O8" value="133.6" lower_limit="24.5" upper_limit="727.2"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6460.4" lower_limit="1521.1" upper_limit="27438.5"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="6712.0" lower_limit="1862.9" upper_limit="24183.8"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="8383.3" lower_limit="4000.7" upper_limit="17566.9"/>
                    <measurement group_id="O8" value="471.9" lower_limit="24.3" upper_limit="9181.4"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4928.0" lower_limit="1015.9" upper_limit="23904.5"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="5417.0" lower_limit="1626.4" upper_limit="18042.7"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="7927.9" lower_limit="4408.1" upper_limit="14258.0"/>
                    <measurement group_id="O8" value="408.1" lower_limit="19.8" upper_limit="8412.5"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34 (n=3, 1, 4, 6, 2, 2, 3, 5, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="992.7" lower_limit="9.5" upper_limit="103353.0"/>
                    <measurement group_id="O2" value="50.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="4480.4" lower_limit="34.4" upper_limit="583150.4"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="7851.2" lower_limit="1669.4" upper_limit="36923.6"/>
                    <measurement group_id="O8" value="287.4" lower_limit="21.2" upper_limit="3888.4"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38 (n=3, 1, 4, 6, 2, 2, 3, 5, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5444.2" lower_limit="634.1" upper_limit="46744.1"/>
                    <measurement group_id="O2" value="50.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="4923.0" lower_limit="65.7" upper_limit="368774.1"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="18040.4" lower_limit="1536.5" upper_limit="211818.5"/>
                    <measurement group_id="O8" value="522.7" lower_limit="30.5" upper_limit="8951.6"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4584.4" lower_limit="2315.0" upper_limit="9078.7"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="2639.5" lower_limit="839.1" upper_limit="8302.7"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="4899.8" lower_limit="1919.8" upper_limit="12505.5"/>
                    <measurement group_id="O8" value="408.9" lower_limit="29.2" upper_limit="5733.6"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2153.0" lower_limit="1108.4" upper_limit="4182.2"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="1603.8" lower_limit="528.8" upper_limit="4864.7"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="2587.5" lower_limit="999.3" upper_limit="6699.7"/>
                    <measurement group_id="O8" value="205.0" lower_limit="27.1" upper_limit="1549.9"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5374.9" lower_limit="2019.8" upper_limit="14303.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="7559.6" lower_limit="2614.6" upper_limit="21857.4"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="10900.6" lower_limit="5915.4" upper_limit="20087.3"/>
                    <measurement group_id="O8" value="611.2" lower_limit="72.8" upper_limit="5131.5"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7811.2" lower_limit="2656.5" upper_limit="22968.2"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="6204.2" lower_limit="1855.1" upper_limit="20749.6"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="8052.1" lower_limit="4251.8" upper_limit="15249.1"/>
                    <measurement group_id="O8" value="458.0" lower_limit="65.9" upper_limit="3180.4"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4668.7" lower_limit="1533.4" upper_limit="14214.4"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="3877.2" lower_limit="1217.4" upper_limit="12347.8"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="3885.1" lower_limit="1951.3" upper_limit="7735.2"/>
                    <measurement group_id="O8" value="227.2" lower_limit="32.6" upper_limit="1582.8"/>
                    <measurement group_id="O9" value="194.0" lower_limit="2.6" upper_limit="14517.7"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=7, 3, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2983.3" lower_limit="954.1" upper_limit="9328.0"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="2488.3" lower_limit="836.1" upper_limit="7405.1"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="2272.0" lower_limit="1192.1" upper_limit="4330.1"/>
                    <measurement group_id="O8" value="231.0" lower_limit="34.2" upper_limit="1559.2"/>
                    <measurement group_id="O9" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82 (n=4, 2, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16812.5" lower_limit="2685.3" upper_limit="105259.9"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="9783.0" lower_limit="3283.5" upper_limit="29148.1"/>
                    <measurement group_id="O4" value="108.7" lower_limit="41.8" upper_limit="282.7"/>
                    <measurement group_id="O5" value="110.7" lower_limit="12.2" upper_limit="1006.4"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="14160.9" lower_limit="8518.5" upper_limit="23540.4"/>
                    <measurement group_id="O8" value="975.6" lower_limit="209.4" upper_limit="4546.5"/>
                    <measurement group_id="O9" value="196.4" lower_limit="30.3" upper_limit="1275.0"/>
                    <measurement group_id="O10" value="385.1" lower_limit="0.0" upper_limit="70941268874642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=4, 2, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14763.7" lower_limit="3422.9" upper_limit="63679.1"/>
                    <measurement group_id="O2" value="188.0" lower_limit="188.0" upper_limit="188.0"/>
                    <measurement group_id="O3" value="7058.6" lower_limit="2484.5" upper_limit="20054.3"/>
                    <measurement group_id="O4" value="94.9" lower_limit="43.4" upper_limit="207.3"/>
                    <measurement group_id="O5" value="136.0" lower_limit="18.7" upper_limit="989.2"/>
                    <measurement group_id="O6" value="109.3" lower_limit="0.0" upper_limit="2265473.2"/>
                    <measurement group_id="O7" value="9998.6" lower_limit="5487.3" upper_limit="18218.7"/>
                    <measurement group_id="O8" value="768.3" lower_limit="126.4" upper_limit="4669.5"/>
                    <measurement group_id="O9" value="383.9" lower_limit="39.8" upper_limit="3700.8"/>
                    <measurement group_id="O10" value="316.9" lower_limit="0.0" upper_limit="4897026295844.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 91 (n=3, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1030.3" lower_limit="51.7" upper_limit="20540.2"/>
                    <measurement group_id="O2" value="50.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 92 (n=4, 2, 11, 6, 5, 2, 8, 5, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6100.2" lower_limit="1730.5" upper_limit="21504.2"/>
                    <measurement group_id="O2" value="277.1" lower_limit="1.1" upper_limit="71502.3"/>
                    <measurement group_id="O3" value="4142.3" lower_limit="1719.9" upper_limit="9976.6"/>
                    <measurement group_id="O4" value="67.6" lower_limit="41.1" upper_limit="111.1"/>
                    <measurement group_id="O5" value="169.3" lower_limit="50.3" upper_limit="569.9"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="4291.7" lower_limit="2472.4" upper_limit="7449.7"/>
                    <measurement group_id="O8" value="391.5" lower_limit="56.2" upper_limit="2724.4"/>
                    <measurement group_id="O9" value="299.8" lower_limit="40.3" upper_limit="2229.5"/>
                    <measurement group_id="O10" value="285.8" lower_limit="0.0" upper_limit="1192613970596.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=7, 3, 11, 6, 5, 2, 7, 4, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2173.6" lower_limit="652.1" upper_limit="7244.7"/>
                    <measurement group_id="O2" value="83.4" lower_limit="9.2" upper_limit="753.5"/>
                    <measurement group_id="O3" value="2224.8" lower_limit="934.8" upper_limit="5295.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O5" value="105.9" lower_limit="40.1" upper_limit="279.5"/>
                    <measurement group_id="O6" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="3167.0" lower_limit="1460.6" upper_limit="6867.2"/>
                    <measurement group_id="O8" value="464.0" lower_limit="40.3" upper_limit="5344.9"/>
                    <measurement group_id="O9" value="256.1" lower_limit="7.6" upper_limit="8678.4"/>
                    <measurement group_id="O10" value="213.8" lower_limit="0.0" upper_limit="22254714647.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=7, 3, 11, 6, 5, 2, 7, 4, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14800.8" lower_limit="4544.9" upper_limit="48199.8"/>
                    <measurement group_id="O2" value="872.2" lower_limit="1.7" upper_limit="459286.2"/>
                    <measurement group_id="O3" value="8306.6" lower_limit="4126.8" upper_limit="16719.9"/>
                    <measurement group_id="O4" value="688.8" lower_limit="118.8" upper_limit="3993.8"/>
                    <measurement group_id="O5" value="4818.1" lower_limit="1026.0" upper_limit="22626.7"/>
                    <measurement group_id="O6" value="1172.0" lower_limit="0.0" upper_limit="54658314329.3"/>
                    <measurement group_id="O7" value="13370.6" lower_limit="6739.1" upper_limit="26527.7"/>
                    <measurement group_id="O8" value="3596.0" lower_limit="469.5" upper_limit="26042.1"/>
                    <measurement group_id="O9" value="448.0" lower_limit="4.4" upper_limit="45743.6"/>
                    <measurement group_id="O10" value="14665.8" lower_limit="0.0" upper_limit="2439205485421.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 110 (n=7, 3, 10, 6, 5, 2, 7, 4, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9185.4" lower_limit="3237.8" upper_limit="26058.4"/>
                    <measurement group_id="O2" value="1257.0" lower_limit="15.9" upper_limit="99324.4"/>
                    <measurement group_id="O3" value="8081.4" lower_limit="4125.7" upper_limit="15829.8"/>
                    <measurement group_id="O4" value="551.4" lower_limit="81.2" upper_limit="3743.4"/>
                    <measurement group_id="O5" value="3726.2" lower_limit="1084.8" upper_limit="12799.5"/>
                    <measurement group_id="O6" value="497.9" lower_limit="0.0" upper_limit="39348525251.6"/>
                    <measurement group_id="O7" value="12209.4" lower_limit="6421.3" upper_limit="23215.2"/>
                    <measurement group_id="O8" value="2504.2" lower_limit="464.4" upper_limit="13505.3"/>
                    <measurement group_id="O9" value="2670.5" lower_limit="0.0" upper_limit="463269086196.1"/>
                    <measurement group_id="O10" value="9454.1" lower_limit="0.0" upper_limit="2972501787380.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 (n=4, 2, 10, 4, 5, 2, 7, 4, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1682.2" lower_limit="38.5" upper_limit="73591.4"/>
                    <measurement group_id="O2" value="1548.4" lower_limit="1.3" upper_limit="1837780.1"/>
                    <measurement group_id="O3" value="5926.3" lower_limit="2682.3" upper_limit="13093.5"/>
                    <measurement group_id="O4" value="831.0" lower_limit="59.8" upper_limit="11548.2"/>
                    <measurement group_id="O5" value="2335.3" lower_limit="715.0" upper_limit="7628.0"/>
                    <measurement group_id="O6" value="258.0" lower_limit="0.0" upper_limit="292460133977.7"/>
                    <measurement group_id="O7" value="8613.4" lower_limit="4540.7" upper_limit="16339.2"/>
                    <measurement group_id="O8" value="1136.1" lower_limit="153.1" upper_limit="8429.8"/>
                    <measurement group_id="O9" value="2929.2" lower_limit="0.0" upper_limit="4137410775629.6"/>
                    <measurement group_id="O10" value="5735.6" lower_limit="0.0" upper_limit="50649360975.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 118 (n=3, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4506.7" lower_limit="59.6" upper_limit="340984.3"/>
                    <measurement group_id="O2" value="50.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 130 (n=6, 3, 10, 5, 5, 2, 7, 4, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3312.9" lower_limit="918.1" upper_limit="11954.2"/>
                    <measurement group_id="O2" value="323.7" lower_limit="4.0" upper_limit="25932.8"/>
                    <measurement group_id="O3" value="2251.0" lower_limit="704.2" upper_limit="7195.9"/>
                    <measurement group_id="O4" value="435.9" lower_limit="45.5" upper_limit="4172.4"/>
                    <measurement group_id="O5" value="1231.0" lower_limit="471.1" upper_limit="3216.5"/>
                    <measurement group_id="O6" value="185.1" lower_limit="0.0" upper_limit="3083418082.5"/>
                    <measurement group_id="O7" value="4197.4" lower_limit="2224.2" upper_limit="7921.3"/>
                    <measurement group_id="O8" value="516.8" lower_limit="42.1" upper_limit="6345.2"/>
                    <measurement group_id="O9" value="1427.2" lower_limit="0.0" upper_limit="61098419244.5"/>
                    <measurement group_id="O10" value="3359.9" lower_limit="0.0" upper_limit="416391434.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 134 (n=5, 3, 8, 4, 5, 2, 6, 4, 1, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5904.2" lower_limit="2760.4" upper_limit="12628.6"/>
                    <measurement group_id="O2" value="4418.8" lower_limit="32.8" upper_limit="595262.2"/>
                    <measurement group_id="O3" value="11064.6" lower_limit="3340.9" upper_limit="36644.9"/>
                    <measurement group_id="O4" value="2718.6" lower_limit="83.6" upper_limit="88360.8"/>
                    <measurement group_id="O5" value="5233.2" lower_limit="2190.3" upper_limit="12503.5"/>
                    <measurement group_id="O6" value="4957.3" lower_limit="0.0" upper_limit="89132252682601"/>
                    <measurement group_id="O7" value="6043.9" lower_limit="1405.3" upper_limit="25993.5"/>
                    <measurement group_id="O8" value="2189.8" lower_limit="39.4" upper_limit="121572.0"/>
                    <measurement group_id="O9" value="4629.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O10" value="14525.7" lower_limit="1101.4" upper_limit="191573.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 136 (n=6, 3, 8, 4, 5, 2, 2, 4, 0, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7816.8" lower_limit="2323.1" upper_limit="26302.4"/>
                    <measurement group_id="O2" value="3706.5" lower_limit="28.6" upper_limit="480359.1"/>
                    <measurement group_id="O3" value="10195.4" lower_limit="3243.3" upper_limit="32049.6"/>
                    <measurement group_id="O4" value="2572.6" lower_limit="101.9" upper_limit="64964.0"/>
                    <measurement group_id="O5" value="4614.4" lower_limit="1945.0" upper_limit="10947.8"/>
                    <measurement group_id="O6" value="3490.4" lower_limit="0.0" upper_limit="129808983536252"/>
                    <measurement group_id="O7" value="18653.9" lower_limit="20.0" upper_limit="17387177.2"/>
                    <measurement group_id="O8" value="1799.7" lower_limit="40.1" upper_limit="80796.0"/>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="6296.3" lower_limit="3108.1" upper_limit="12754.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 142 (n=3, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2353.6" lower_limit="164.1" upper_limit="33761.9"/>
                    <measurement group_id="O2" value="12571.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 146 (n=3, 2, 9, 4, 5, 2, 2, 4, 0, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6813.3" lower_limit="1976.2" upper_limit="23490.5"/>
                    <measurement group_id="O2" value="979.6" lower_limit="447.2" upper_limit="2146.1"/>
                    <measurement group_id="O3" value="7269.6" lower_limit="2546.0" upper_limit="20756.9"/>
                    <measurement group_id="O4" value="3252.9" lower_limit="156.4" upper_limit="67657.2"/>
                    <measurement group_id="O5" value="3163.7" lower_limit="1153.6" upper_limit="8676.4"/>
                    <measurement group_id="O6" value="1338.7" lower_limit="0.0" upper_limit="2432477307830.6"/>
                    <measurement group_id="O7" value="9664.4" lower_limit="6383.5" upper_limit="14631.5"/>
                    <measurement group_id="O8" value="1022.4" lower_limit="41.4" upper_limit="25279.5"/>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="4277.9" lower_limit="538.3" upper_limit="33999.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=6, 3, 8, 4, 4, 2, 2, 4, 0, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2998.5" lower_limit="853.4" upper_limit="10536.3"/>
                    <measurement group_id="O2" value="1410.5" lower_limit="237.4" upper_limit="8381.7"/>
                    <measurement group_id="O3" value="4600.8" lower_limit="1798.3" upper_limit="11770.3"/>
                    <measurement group_id="O4" value="2532.8" lower_limit="97.0" upper_limit="66111.6"/>
                    <measurement group_id="O5" value="2880.8" lower_limit="1242.7" upper_limit="6678.3"/>
                    <measurement group_id="O6" value="737.9" lower_limit="0.0" upper_limit="11966762355531"/>
                    <measurement group_id="O7" value="6706.3" lower_limit="164.9" upper_limit="272699.3"/>
                    <measurement group_id="O8" value="706.6" lower_limit="41.7" upper_limit="11981.1"/>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="2643.6" lower_limit="1902.1" upper_limit="3674.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 160 (n=5, 3, 7, 4, 2, 2, 1, 2, 0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6305.4" lower_limit="2243.7" upper_limit="17719.5"/>
                    <measurement group_id="O2" value="1833.3" lower_limit="101.1" upper_limit="33260.5"/>
                    <measurement group_id="O3" value="6945.3" lower_limit="3865.8" upper_limit="12477.7"/>
                    <measurement group_id="O4" value="4810.2" lower_limit="366.0" upper_limit="63211.9"/>
                    <measurement group_id="O5" value="4080.8" lower_limit="0.0" upper_limit="11159747036.1"/>
                    <measurement group_id="O6" value="3632.1" lower_limit="434.2" upper_limit="30382.4"/>
                    <measurement group_id="O7" value="7731.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O8" value="1779.5" lower_limit="362.3" upper_limit="8741.0"/>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="2518.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 162 (n=6, 3, 8, 4, 4, 2, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8513.5" lower_limit="2074.4" upper_limit="34940.7"/>
                    <measurement group_id="O2" value="1586.1" lower_limit="125.6" upper_limit="20025.2"/>
                    <measurement group_id="O3" value="10450.4" lower_limit="5734.0" upper_limit="19046.0"/>
                    <measurement group_id="O4" value="6398.1" lower_limit="417.4" upper_limit="98070.7"/>
                    <measurement group_id="O5" value="6453.5" lower_limit="1202.3" upper_limit="34641.3"/>
                    <measurement group_id="O6" value="2362.8" lower_limit="0.4" upper_limit="13656178.6"/>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 171 (n=3, 2, 7, 4, 4, 2, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8602.3" lower_limit="4440.7" upper_limit="16664.0"/>
                    <measurement group_id="O2" value="739.7" lower_limit="32.9" upper_limit="16622.6"/>
                    <measurement group_id="O3" value="7551.2" lower_limit="3117.9" upper_limit="18288.2"/>
                    <measurement group_id="O4" value="7027.0" lower_limit="485.8" upper_limit="101644.6"/>
                    <measurement group_id="O5" value="4351.5" lower_limit="1055.3" upper_limit="17944.0"/>
                    <measurement group_id="O6" value="1404.9" lower_limit="0.0" upper_limit="328577560.1"/>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 172 (n=2, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1074.9" lower_limit="0.1" upper_limit="8576667.2"/>
                    <measurement group_id="O2" value="2981.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 182 (n=3, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1944.9" lower_limit="81.6" upper_limit="46329.0"/>
                    <measurement group_id="O2" value="2555.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 184 (n=3, 2, 6, 4, 3, 2, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7062.8" lower_limit="5311.4" upper_limit="9391.7"/>
                    <measurement group_id="O2" value="636.6" lower_limit="4.1" upper_limit="98882.9"/>
                    <measurement group_id="O3" value="3378.1" lower_limit="1687.3" upper_limit="6763.1"/>
                    <measurement group_id="O4" value="5682.1" lower_limit="345.0" upper_limit="93583.6"/>
                    <measurement group_id="O5" value="5064.1" lower_limit="3850.7" upper_limit="6659.9"/>
                    <measurement group_id="O6" value="824.3" lower_limit="0.0" upper_limit="32731187354.9"/>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 186 (n=2, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3653.9" lower_limit="0.0" upper_limit="8947070499.4"/>
                    <measurement group_id="O2" value="13166.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=2, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3033.0" lower_limit="0.0" upper_limit="11447766146.8"/>
                    <measurement group_id="O2" value="14096.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 197 (n=3 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2074.7" lower_limit="78.6" upper_limit="54786.4"/>
                    <measurement group_id="O2" value="5502.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 210 (n=2, 1, 0, 0, 0, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1291.4" lower_limit="0.0" upper_limit="404404006.6"/>
                    <measurement group_id="O2" value="1997.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O5" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O6" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O7" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O8" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O9" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O10" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Anti-A-beta IgM (Immunoglobulin M) Titer at Specified Visits</title>
        <description>Geotmetric mean of anti-a-beta IgM titer from baseline of the preceding studies through the end of this study</description>
        <time_frame>Baseline of preceding studies to month 24 of this study (Week 210)</time_frame>
        <population>The immunogenicity analysis population consisted of those in the safety analysis population who had baseline immunogenicity evaluation in the preceding study and at least one immunogenicity evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the IgM data were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>QS-21+(3 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg ACC-001+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>QS-21+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>PBS+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O7">
            <title>30 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O8">
            <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O9">
            <title>QS-21+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O10">
            <title>PBS+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21(50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-A-beta IgM (Immunoglobulin M) Titer at Specified Visits</title>
          <description>Geotmetric mean of anti-a-beta IgM titer from baseline of the preceding studies through the end of this study</description>
          <population>The immunogenicity analysis population consisted of those in the safety analysis population who had baseline immunogenicity evaluation in the preceding study and at least one immunogenicity evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the IgM data were not summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 26, 52, 78 and 104.</title>
        <description>The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11, with higher scores indicating a greater degree of impairment. The total score ranges from 0 (no impairment) to 70 (worst impairment).</description>
        <time_frame>Baseline up to 24 Months</time_frame>
        <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the ADAS-Cog scores were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>QS-21+(3 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg ACC-001+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>QS-21+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>PBS+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O7">
            <title>30 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O8">
            <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O9">
            <title>QS-21+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O10">
            <title>PBS+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21(50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 26, 52, 78 and 104.</title>
          <description>The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11, with higher scores indicating a greater degree of impairment. The total score ranges from 0 (no impairment) to 70 (worst impairment).</description>
          <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the ADAS-Cog scores were not summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 26, 52,78 and 104.</title>
        <description>The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
        <time_frame>Baseline up to 24 Months</time_frame>
        <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the DAD scores were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>QS-21+(3 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg ACC-001+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>QS-21+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>PBS+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O7">
            <title>30 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O8">
            <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O9">
            <title>QS-21+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O10">
            <title>PBS+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21(50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 26, 52,78 and 104.</title>
          <description>The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
          <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the DAD scores were not summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 26, 52, 78 and 104.</title>
        <description>The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit – y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants’ observed baseline scores in the study.</description>
        <time_frame>Baseline up to 24 Months</time_frame>
        <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the NTB scores were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>QS-21+(3 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg ACC-001+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>QS-21+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>PBS+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O7">
            <title>30 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O8">
            <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O9">
            <title>QS-21+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O10">
            <title>PBS+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21(50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 26, 52, 78 and 104.</title>
          <description>The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit – y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants’ observed baseline scores in the study.</description>
          <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the NTB scores were not summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 12, 26, 36, 52, 66, 78, 91 and 104.</title>
        <description>The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points, and any score equal to or lower than 26 points indicates cognitive impairment.</description>
        <time_frame>Baseline up to 24 Months</time_frame>
        <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the MMSE scores were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>3 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O2">
            <title>QS-21+(3 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O3">
            <title>10 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O4">
            <title>10 μg ACC-001+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (10 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O5">
            <title>QS-21+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O6">
            <title>PBS+(10 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O7">
            <title>30 μg ACC-001+QS-21</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O8">
            <title>30 μg ACC-001+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of active vaccine ACC-001(30 μg) in the preceding studies and ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O9">
            <title>QS-21+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
          <group group_id="O10">
            <title>PBS+(30 μg ACC-001+QS-21)</title>
            <description>A group of participants who received IM injection of PBS in the preceding studies and active vaccine ACC-001(30 μg) + adjuvant QS-21(50 μg) in this study (Day 1, month 6, 12, and 18)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 12, 26, 36, 52, 66, 78, 91 and 104.</title>
          <description>The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points, and any score equal to or lower than 26 points indicates cognitive impairment.</description>
          <population>The efficacy analysis population was all of the participants who received at least one injection in this study and had baseline efficacy evaluation in the preceding study and at least one efficacy evaluation post injection. Since the study was early terminated and the data could not be obtained as planned, the MMSE scores were not summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>3μg ACC-001 Treat</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) both in the preceding studies and in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="E2">
          <title>3μg Control</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) in the preceding studies and acctive vaccine ACC-001 (3 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="E3">
          <title>10ug ACC-001 Treat</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001 (10 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="E4">
          <title>10μg Control</title>
          <description>A group of participants who received IM injection of adjuvant QS-21 (50 μg) or PBS in the preceding studies and active vaccine ACC-001(10 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="E5">
          <title>30μg ACC-001 Treat</title>
          <description>A group of participants who received IM injection of active vaccine ACC-001 (30 μg) with or without adjuvant QS-21 (50 μg) in the preceding studies and ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="E6">
          <title>30μg Control</title>
          <description>A group of participants who received IM injection of adjuvant QS-21(50 μg) or PBS in the preceding studies and active vaccine ACC-001 (30 μg) + adjuvant QS-21 (50 μg) in this study (Day 1, month 6, 12, and 18)</description>
        </group>
        <group group_id="E7">
          <title>Total</title>
          <description>All participants</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Polychondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Impulsive behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphocyte morphology abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Metamyelocyte percentage increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Apraxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cerebral microhaemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cerebral ventricle dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Logorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

